Support intervention for patients with malignant brain tumors
NeuroPathways: An Information and Support Intervention for Patients With Malignant Brain Tumors
This study is testing a support program that gives information and coaching to help people cope with a recent diagnosis of malignant brain tumors.
Quick facts
| Phase | Not applicable |
|---|---|
| Study type | Interventional |
| Enrollment | 50 (estimated) |
| Ages | 18 Years and up |
| Sex | All |
| Sponsor | Massachusetts General Hospital Academic / other |
| Locations | 1 site (Boston, Massachusetts) |
| Trial ID | NCT05976490 on ClinicalTrials.gov |
What this trial studies
This study tests an information and support intervention aimed at helping patients cope with a recent diagnosis of malignant brain tumors. It includes access to an information guide and one-on-one coaching sessions to evaluate its feasibility and acceptability. Participants will engage in coaching, utilize the guide, and complete surveys at multiple time points, with some providing feedback through exit interviews. The study aims to refine the intervention based on initial feedback and explore its effects on psychological and cognitive outcomes.
Who should consider this trial
Good fit: Ideal candidates are adults aged 18 and older who are patients at Massachusetts General Hospital and have been diagnosed with a primary malignant brain tumor within the last six weeks.
Not a fit: Patients who are unable to provide informed consent due to severe cognitive impairment or those deemed inappropriate for the study by their oncologist may not benefit from this intervention.
Why it matters
Potential benefit: If successful, this intervention could significantly improve coping skills and psychological well-being for patients diagnosed with malignant brain tumors.
How similar studies have performed: While this specific intervention is novel, similar supportive care approaches have shown promise in improving patient outcomes in other studies.
Eligibility criteria
Show full inclusion / exclusion criteria
Inclusion Criteria: * Age ≥18 * Massachusetts General Hospital Cancer Center patient * Within 6 weeks of diagnosis with a primary malignant brain tumor * Able to speak and read in English Exclusion Criteria: * Inability to provide informed consent as assessed by the study team (e.g., due to neurological impairment such as severe cognitive impairment/dementia or moderate-to-severe receptive aphasia) * Deemed inappropriate to approach by patient's oncologist or study PI
Where this trial is running
Boston, Massachusetts
- Massachusetts General Hospital Cancer Center — Boston, Massachusetts, United States (Recruiting)
Study contacts
- Principal investigator: Deborah A Forst, MD — Massachusetts General Hospital
- Study coordinator: Deborah A Forst, MD
- Email: dforst@partners.org
- Phone: 617-724-4000
How to participate
- Review the eligibility criteria above with your treating physician.
- Visit the official trial page on ClinicalTrials.gov for the most current contact information and recruitment status.
- Contact the listed study coordinator or principal investigator to request pre-screening. Pre-screening is free and never obligates you to enroll.